Core Viewpoint - The company has successfully completed the share purchase agreements, resulting in the issuance of a total of 2.753 billion shares [1] Group 1: Share Purchase Agreements - The board of directors announced that all conditions precedent for Share Purchase Agreement I and Share Purchase Agreement II have been met [1] - The share purchase agreements were completed on October 2, 2025 [1] - A total of 2.753 billion shares have been issued as consideration shares [1] Group 2: Convertible Bonds - The company received a conversion notice from bondholders regarding the full exercise of their conversion rights under the convertible bond issue [1] - The principal amount of HKD 1.086 billion in convertible bonds was converted into 5.173 billion shares at a conversion price of HKD 0.21 per share [1] - After completing the necessary administrative procedures for the issuance of conversion shares, the company issued 5.173 billion conversion shares to bondholders on October 2, 2025 [1]
大成生化科技(00809)完成根据特别授权发行代价股份及转换可换股债券